Balyasny Asset Management LLC Ocugen, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.5 - $1.83 $55,418 - $202,829	110,836 New	110,836 $181,000
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.62 $12,028 - $18,644	-30,071 Reduced 70.79%	12,407 $4,000
Q2 2023 Aug 14, 2023	BUY	$0.45 - $0.88 $19,115 - $37,380	42,478 New	42,478 $22,000
Q4 2022 Feb 14, 2023	BUY	$1.11 - $1.87 $14,227 - $23,969	12,818 Added 18.78%	81,055 $105,000
Q3 2022 Nov 14, 2022	BUY	$1.75 - $3.1 $47,223 - $83,653	26,985 Added 65.42%	68,237 $121,000
Q2 2022 Aug 15, 2022	BUY	$1.83 - $3.45 $75,491 - $142,319	41,252 New	41,252 $94,000

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.